Advita Lifescience has a total of 33 patents globally, out of which 1 have been granted. Of these 33 patents, more than 75% patents are active. Europe (EPO) is where Advita Lifescience has filed the maximum number of patents, followed by Canada and United States of America. Parallelly, Europe (EPO) seems to be the main focused R&D centre and Germany is the origin country of Advita Lifescience.
Advita Lifescience founded in 019, Advita Lifescience develops diagnostic and pharmaceutical technologies focused on rare lung diseases. The company provides solutions for disease detection and therapy improvement, while advancing products for both human and veterinary medicine.
Do read about some of the most popular patents of Advita Lifescience which have been covered by us in this article and also you can find Advita Lifescience patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Advita Lifescience patent portfolio.
How many patents does Advita Lifescience have?
Advita Lifescience has a total of 33 patents globally. These patents belong to 5 unique patent families. Out of 33 patents, 25 patents are active.
How Many Patents did Advita Lifescience File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Advita Lifescience Applications Filed | Advita Lifescience Patents Granted |
| 2024 | – | – |
| 2023 | 1 | – |
| 2022 | 8 | 1 |
| 2021 | 12 | – |
| 2020 | 12 | – |
How many Advita Lifescience patents are Alive/Dead?
Worldwide Patents
How Many Patents did Advita Lifescience File in Different Countries?
Countries in which Advita Lifescience Filed Patents
| Country | Patents |
| Europe (EPO) | 4 |
| Canada | 3 |
| United States of America | 3 |
| Korea (South) | 2 |
| Singapore | 2 |
| Mexico | 2 |
| South Africa | 2 |
| China | 2 |
| Brazil | 2 |
| Hong Kong (S.A.R.) | 2 |
| Israel | 2 |
| Russia | 1 |
| India | 1 |
| Australia | 1 |
| Switzerland | 1 |
Where are Research Centres of Advita Lifescience Patents Located?
Advita Lifescience Best Patent
WO2021152119A1 is the most popular patent in the Advita Lifescience portfolio. It has received 5 citations so far from company like ReViSan Healthcare Gmbh.
What Percentage of Advita Lifescience US Patent Applications were Granted?
Advita Lifescience (Excluding its subsidiaries) has filed 3 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0%.
Below are the key stats of Advita Lifescience patent prosecution at the USPTO.
Which Law Firms are managing US Patents for Advita Lifescience?
| Law Firm | Total Applications | Success Rate |
| Sterne Kessler Goldstein & Fox Pllc | 3 | 0% |
List of Advita Lifescience Patents
| Publication Number | Title |
| US20240181014A1 | Use Of Aviptadil Alone Or In Combination With Alpha Lipoic Acid As A Therapeutic Medicament For Post-Viral Infection Syndrome |
| US20230103704A1 | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Issues |
| US20220202906A1 | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| EP4326310A1 | Use Of Aviptadil Alone Or In Combination With Alpha Lipoic Acid As A Therapeutic Medicament For Post-Viral Infection Syndrome |
| EP4096700A1 | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| EP3965801A1 | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| CN115066254A | Human Anti-Inflammatory Peptides For Inhaled Treatment Of Inflammatory Lung Disease |
| CN114144195A | Vasoactive Intestinal Peptide(Vip)Use For The Treatment Of Drug-Induced Pneumonia |
| CH717180B1 | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis. |
| CA3214539A1 | Use Of Aviptadil Alone Or In Combination With Alpha Lipoic Acid As A Therapeutic Medicament For Post-Viral Infection Syndrome |
| CA3166275A1 | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| CA3138891A1 | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| HK40081015A | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| BR112022014892A2 | Human Anti-Inflammatory Peptides For The Inhaled Treatment Of Inflammatory Pulmonary Diseases |
| MX2022009328A | Human Anti-Inflammatory Peptides For Inhalatory Treatment Of Inflammatory Lung Diseases |
| HK40070179A | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| KR20220134764A | Human Anti-Inflammatory Peptides For Inhaled Treatment Of Inflammatory Pulmonary Disease |
| IL295115A | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| SG11202251573QA | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| ZA202207786A | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| MX2021013496A | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| IL287854A | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| ZA202108033A | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| IN202227048878A | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| AU2021215045A1 | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| EP3858372A1 | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| WO2022224172A1 | Use Of Aviptadil Alone Or In Combination With Alpha Lipoic Acid As A Therapeutic Medicament For Post-Viral Infection Syndrome |
| WO2021152119A1 | Human Anti-Inflammatory Peptides For The Inhalatory Treatment Of Inflammatory Pulmonary Diseases |
| WO2020225246A1 | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| KR20220005495A | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Interstitial Pneumonia |
| BR112021022170A2 | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonite |
| SG11202111925RA | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
| RU2021135128A | Vasoactive Intestinal Peptide (Vip) For Use In The Treatment Of Drug-Induced Pneumonitis |
What are Advita Lifescience key innovation segments?
What Technologies are Covered by Advita Lifescience?
The chart below distributes patents filed by Advita Lifescience in different countries on the basis of the technology protected in patents. It also represents the markets where Advita Lifescience thinks it’s important to protect particular technological inventions.
R&D Focus: How has Advita Lifescience search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Advita Lifescience?
